Endometrial Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Adjuvant Chemo in Endometrial Cancer: Benefit Only for Some - Medscape



Oncology Nurse Advisor
 
Adjuvant Chemo in Endometrial Cancer: Benefit Only for Some 
Medscape
In addition, the severity and duration of the toxicity associated with chemoradiotherapy, together with the protracted treatment course, suggest that the new approach should be carefully discussed with cancer patients who have stage III, high-risk ...
5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy Oncology Nurse Advisor

all 2 news articles » 


No OS Benefit With Chemoradiotherapy in High-Risk Endometrial Cancer - OncLive



No OS Benefit With Chemoradiotherapy in High-Risk Endometrial Cancer 
OncLive
de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial [published ...

 


Radiation Role Remains Uncertain in High-Risk Endometrial Cancer - OncLive



OncLive
 
Radiation Role Remains Uncertain in High-Risk Endometrial Cancer 
OncLive
OncLive: Please discuss the use of external beam radiation therapy in high-risk patients with endometrial cancer. Mutch: I am in a debate [at this meeting] on whether there is utility in giving patients with high-risk endometrial cancer radiation ...

 


Geography, Race, and Genetic Variation in Endometrial Cancer - www.oncnursingnews.com/



www.oncnursingnews.com/
 
Geography, Race, and Genetic Variation in Endometrial Cancer 
www.oncnursingnews.com/
Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group. A study done at SUNY Downstate Hospital recently found that black women of Caribbean descent with type I or type ...

 


Women with stage III endometrial cancer may benefit from adjuvant chemoradiotherapy - medwireNews



Women with stage III endometrial cancer may benefit from adjuvant chemoradiotherapy 
medwireNews
This difference was mainly driven by an 11% absolute improvement with adjuvant chemoradiotherapy over radiotherapy alone in a subgroup of 295 women with stage III endometrial cancer, the team notes. The improvement was deemed ?clinically relevant ...

 


Study Highlights Impact of Race, Geography on Genetic Variation in Endometrial Cancer - OncLive



OncLive
 
Study Highlights Impact of Race, Geography on Genetic Variation in Endometrial Cancer 
OncLive
An analysis of black women of Caribbean descent with type I or type II endometrial cancer showed that this population expressed significant differences in genetic variations compared with a nationwide population of patients with endometrial cancer ...

 


Dr. Haldorsen on Overcoming Challenges With Imaging in Endometrial Cancer - OncLive



OncLive
 
Dr. Haldorsen on Overcoming Challenges With Imaging in Endometrial Cancer 
OncLive
Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses overcoming challenges with imaging in endometrial cancer. Preoperative imaging is an important part of the primary diagnostic work-up of endometrial cancer, as it ...

 


Dr. Mutch Discusses Radiation Versus Targeted Therapy in Endometrial Cancer - OncLive



OncLive
 
Dr. Mutch Discusses Radiation Versus Targeted Therapy in Endometrial Cancer 
OncLive
David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses whether or not a patient with high-risk ...
Endometrial Cancer Therapeutics Market Is Forecasted To Reach USD 27 Billion By 2023: Hexa Reports MilTech

all 3 news articles » 


Uterine Cancer Market Spotlight 2017-2027: Key Pipeline Drugs, Clinical Trials, Patent Information, Disease ... - Business Wire (press release)



Uterine Cancer Market Spotlight 2017-2027: Key Pipeline Drugs, Clinical Trials, Patent Information, Disease ... 
Business Wire (press release)
The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II. Therapies in the pipeline for uterine cancer focus on a variety of targets. The vast majority of pipeline drugs in development are administered ...

and more » 


Dr. Taylor on the Future of Treatments for Endometrial Cancer - OncLive



OncLive
 
Dr. Taylor on the Future of Treatments for Endometrial Cancer 
OncLive
Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the future of treatments for patients with endometrial cancer. There are exciting treatments coming forward, both in terms of systemic targeted agents and new ...